Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Similarity Data To Be Presented At 2021 ARVO Meeting

Eye
The first biosimilar to Lucentis is expected to launch in the US in the second half of 2021 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products